Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab monotherapy versus conventional step-up therapy in moderate to severe ulcerative colitis
2009-010065-23Phase 3Completed
- Sponsor
- Essex Bio-Technology Limited
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of infliximab in autoimmune colitis (2 arms), sponsored by Essex Bio-Technology Limited. Primary endpoint: Composite primary efficacy endpoint. Started Apr 2009; status: completed.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2009-010065-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010065-23.